Team:NJU China/Project/Liver

From 2013.igem.org

Revision as of 15:36, 28 October 2013 by Tafeiry (Talk | contribs)

<!DOCTYPE html> NJU_China








Liver:

For liver targeting, we need to first find a protein specifically recognize hepatic cells. Since Heptitis B virus can infect hepatic cells distinctively, and from recent study[1], we knew that HBV recognizes the hepatic cells via the interaction between the pre-S1 of the HBV envelop protein and NTCP receptor of the hepatic cells. We tried to engineer the pre-S1 from HBV envelope protein to the lamp 2b.
Therefore we cloned the pre-S1 into lamp 2b, and we choose pcDNA 3.1(+) as our backbone.



Experimental procedures and Results :

1. Exosome morphology under TEM

The exosomes produced by the transfected HEK 293T cells was collected 24h post transfection. The morphology and diameter of the exosomes were examined by TEM.

As shown in Fig.1, the diameter of the exosomes is around 50nm and it was round.



Figure.1 TEM micrographs of the exosomes isolated from 293T cell culture medium after transfection of pre-S1 plasmid.

2. In vitro evidence for the entry of pre-S1 exosomes into the HepG2 cell

As shown in Fig.2, by labeling the exosomes with DiI-C16 (red) and HepG2 nucleus with DAPI(blue), it can be seen that the exosomes successfully get into the HepG2 cells.


Fig.2 Confocal microscopy image of the internalization of fluorescently labeled MVs into HepG2 cells. 293T cells were labeled with DiI-C16 (red) and then cultured in RPMI 1640 medium supplemented with 10% FBS. After 4 hours, the supernatants were collected and centrifuged to harvest exosomes. 293T exosomes were resuspended in MCDB-131 medium and incubated with HepG2 cells at 37°C. After incubation for 2 hours, HepG2 cells were washed, fixed, and observed under confocal microscopy.

3. In vivo evidence for the liver-specific delivery of siRNA by pre-S1 exosome

In this part of experiments, we investigated the potential for exosome-mediated systemic siRNA delivery to liver.

To characterize the tissue distribution, we chose GFP(Green Fluorescent Protein) mice as our animal model and anti-GFP siRNA(which can silence the GFP gene ) as our ‘killing device’.

We first collected three kinds of exosomes:1) empty exosomes (no targeting peptide outside and no anti-GFP siRNA inside)2) exsosomes with anti-GFP siRNA inside only(no targeting ability) 3) exsosomes with both anti-GFP siRNA inside and targeting peptides pre s1 on the surface.

Three groups of mice were injected intravenously with three kinds of exosomes respectively. Finally, by using histological section technique and fluorescence microscope, we directly observed the expression level of GFP gene in mice liver from different experimental groups.

Given the same cell number and different expression level of GFP gene, we could concluded that injection of empty exosome did not lead to any significant change of GFP expression in mice liver (Fig.3A). Similarly, the siRNA-contained-only exosome induced a slight, but non-significant GFP silencing in liver (Fig.3B). By contrast, injection of siRNA-pre-S1 exosomes resulted in significant knockdown of GFP mRNA in liver, where the target of preS1 expressed (Fig.3C). These results successfully demonstrated that our modified exosomes could specifically deliver siRNA into liver and thus silence target gene.


Fig.3 In vivo evidence for the liver-specific delivery of siRNA by pre-S1 exosome. Mice were intravenously injected with anti-GFP siRNA encapsulated in pre-S1 exosomes. Figures above show the section of liver tissue. Upper ones were captured under dark field and lower ones were captured under light field in the same visual field. From the comparison between dark field picture and light field picture, we can easily see the different expression level of GFP between different groups. A was injected wih empty exosomes (no targeting peptide outside and no anti-GFP siRNA inside). B was injected with exsosomes with anti-GFP siRNA inside only(no targeting ability) C was injected wih exsosomes with both anti-GFP siRNA inside and targeting peptides pre-s1 on the surface.